BATLYG Trademark

Trademark Overview


On Tuesday, November 20, 2018, a trademark application was filed for BATLYG with the United States Patent and Trademark Office. The USPTO has given the BATLYG trademark a serial number of 88201472. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 23, 2022. This trademark is owned by Eli Lilly and Company. The BATLYG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
batlyg

General Information


Serial Number88201472
Word MarkBATLYG
Filing DateTuesday, November 20, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 23, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 19, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 10, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, May 23, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 23, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 21, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 20, 2021SOU EXTENSION 5 GRANTED
Thursday, September 16, 2021SOU EXTENSION 5 FILED
Thursday, September 16, 2021TEAS EXTENSION RECEIVED
Wednesday, March 24, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 22, 2021SOU EXTENSION 4 GRANTED
Monday, March 22, 2021SOU EXTENSION 4 FILED
Monday, March 22, 2021TEAS EXTENSION RECEIVED
Friday, September 25, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 24, 2020SOU EXTENSION 3 GRANTED
Wednesday, September 16, 2020SOU EXTENSION 3 FILED
Thursday, September 24, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 16, 2020TEAS EXTENSION RECEIVED
Saturday, March 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 19, 2020SOU EXTENSION 2 GRANTED
Thursday, March 19, 2020SOU EXTENSION 2 FILED
Thursday, March 19, 2020TEAS EXTENSION RECEIVED
Thursday, September 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2019SOU EXTENSION 1 GRANTED
Tuesday, September 24, 2019SOU EXTENSION 1 FILED
Tuesday, September 24, 2019TEAS EXTENSION RECEIVED
Tuesday, April 16, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 19, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 19, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 30, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 8, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 2, 2019ASSIGNED TO EXAMINER
Monday, December 10, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, November 23, 2018NEW APPLICATION ENTERED IN TRAM